FEMASYS INC. - COMMON STOCK

Femasys Inc. to Showcase Four Products at the American College of Obstetricians and Gynecologists Annual Clinic & Scientific Meeting

11 май 2023 08:30:00 Источник Nasdaq GlobeNewswire

Femasys’ FemCerv Endocervical Tissue Sampler for Cervical Cancer Diagnosis Receives Product Approval in Canada

03 май 2023 08:30:00 Источник Nasdaq GlobeNewswire

Femasys Inc. to Showcase FemCerv at the Annual Meeting for the American Society for Colposcopy and Cervical Pathology

01 май 2023 16:05:00 Источник Nasdaq GlobeNewswire

Femasys Announces $3.9 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

19 апр 2023 08:00:00 Источник Nasdaq GlobeNewswire

Femasys’ FemaSeed Localized Directional Insemination for Infertility Receives Product Approval in Canada

18 апр 2023 08:00:01 Источник Nasdaq GlobeNewswire

Femasys Inc. Announces Financial Results for the Year Ended December 31, 2022 and Provides Corporate Update

30 мар 2023 08:00:00 Источник Nasdaq GlobeNewswire

Femasys Inc. to Participate in “The Post-Roe Fertility Journey” Panel Discussion at SXSW 2023

09 мар 2023 08:00:02 Источник Nasdaq GlobeNewswire

Femasys Inc. Announces Commercial Availability of its FemCath Intrauterine Device

19 дек 2022 09:00:00 Источник Nasdaq GlobeNewswire

Femasys Inc. Reports Encouraging Promotional Launch of FemCerv at AAGL Based on Positive Reception by Gynecologic Physicians and Surgeons

12 дек 2022 08:30:00 Источник Nasdaq GlobeNewswire

Femasys Inc. Announces Enrollment is over 25% Complete for FemaSeed® De Novo Trial Following Updated Strategic Study Design

29 ноя 2022 07:00:01 Источник Nasdaq GlobeNewswire

Femasys Inc. to Present at the Piper Sandler 34th Annual Healthcare Conference

21 ноя 2022 08:30:00 Источник Nasdaq GlobeNewswire

Femasys Inc. Announces Financial Results for the Third Quarter Ended September 30, 2022 and Provides Corporate Update

10 ноя 2022 08:44:47 Источник Nasdaq GlobeNewswire

Femasys Inc. Provides Strategic Update on its FemaSeed® Pivotal Trial Design to Expedite Clinical Program Advancement

20 окт 2022 08:00:02 Источник Nasdaq GlobeNewswire

Femasys to Participate in 78th Annual American Society for Reproductive Medicine (ASRM) Scientific Congress

14 окт 2022 16:05:00 Источник Nasdaq GlobeNewswire

Femasys Inc. Announces the Appointment of Christine Thomas as Senior Vice President of Regulatory and Clinical Affairs

12 окт 2022 08:00:02 Источник Nasdaq GlobeNewswire

Femasys Inc. Announces Enrollment Completion for Stage 2 Study of FemBloc for Permanent Birth Control

06 окт 2022 08:01:00 Источник Nasdaq GlobeNewswire

Femasys Inc. Announces the Commercial Availability of FemCerv® for Cervical Cancer Screening and Expands Management Team

29 сен 2022 08:00:01 Источник Nasdaq GlobeNewswire

Femasys Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference

01 сен 2022 16:05:01 Источник Nasdaq GlobeNewswire

Femasys Inc. Announces Financial Results for the Second Quarter Ended June 30, 2022 and Provides Corporate Update

10 авг 2022 16:05:01 Источник Nasdaq GlobeNewswire

Femasys To Participate in Upcoming BTIG Biotechnology Conference

03 авг 2022 08:00:01 Источник Nasdaq GlobeNewswire